leisure time -WSS

leisure time

author：entertainment 2025-10-02 23:31:22 - browse：7

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Readout LOUD podcast: ALS dilemma, first MASH drug, and more

WSS

What happened to the House vote on health price transparency?

As AI in medicine takes off, can 'human in the loop' prevent harm?

Readout Newsletter: CAR

Grad students accuse University of California of wage theft

How many hemophilia patients actually want gene therapy?

FDA panel to weigh safety of artificial wombs for preterm births

focus

leisure time

Wikipedia

Virginia high school admissions case could be legal follow

Why depression after traumatic brain injury is distinct

New air purifier tech could be key to improving indoor air quality

WuXi out of biotech trade group, U.S. and China relations to blame

New air purifier tech could be key to improving indoor air quality

Amid AI frenzy, a top HHS official's quest to create safeguards

After affirmative action ruling, medical educators look to 'holistic review'

Chamber of Commerce, DOJ clash in court over drug prices

Walensky prepares to leave CDC — and Congress — behind

John Green on his newest strategy for fighting tuberculosis

leisure time

President Biden's budget: Here's what you might have missed

As AI in medicine takes off, can 'human in the loop' prevent harm?

Information blocking fines are now fair game in health care

Change Healthcare outage fallout shows need for new oversight

'A game

FDA weighs limits of animal data in assessing artificial wombs

focus

focus

hotspot

focus